Security
Helix Acquisition Corp. Class A Ordinary Shares · HLXA
HLXANASDAQCommon stockHistorical · closed Apr 5, 2022CIK 1821586Updated Oct 6, 2026
Name history
Helix Acquisition Corp · through Mar 31, 2022
Current security for this SEC filerMLTX · NASDAQ
HLXA price & chart
Historical security
This listing closed Apr 5, 2022. Live provider charts are shown only for current listings.
Current security: MLTX
About the company
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The Company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis - conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01
SCHEDULE 13G - filed by T. Rowe Price Investment Management, Inc. regarding MoonLake Immunotherapeutics
SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding MoonLake Immunotherapeutics
S-8 filing
S-3ASR filing
Show 5 more recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Other Events
Items 8.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 414,335,000Source | 518,213,328Source | 573,947,000Source | 460,096,000Source | 544,877,690Source | 400,374,000Source | 511,262,000Source | 564,117,138Source | 424,433,000Source | 477,933,282Source | 526,540,115Source | 76,843,301Source |
| Property, Plant and Equipment, NetUSD | 622,000Source | 581,378Source | 487,000Source | 667,000Source | 481,705Source | 532,000Source | 711,000Source | 509,816Source | 577,000Source | 722,226Source | 320,865Source | 49,389Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 350,736,000Source | 375,656,291Source | 477,905,000Source | 306,681,000Source | 342,791,142Source | 298,490,000Source | 271,566,000Source | 458,441,051Source | 334,517,000Source | 180,426,449Source | 451,169,337Source | 39,505,627Source |
| Assets, CurrentUSD | 411,215,000Source | 512,316,178Source | 570,038,000Source | 455,481,000Source | 536,881,881Source | 396,641,000Source | 506,264,000Source | 553,589,970Source | 421,694,000Source | 474,288,845Source | 514,167,302Source | 76,511,332Source |
| Operating Lease, Right-of-Use AssetUSD | 1,911,000Source | 3,251,197Source | 2,078,000Source | 2,251,000Source | 3,384,953Source | 1,857,000Source | 2,589,000Source | 3,698,514Source | 1,566,000Source | 2,922,211Source | 3,628,480Source | 282,580Source |
| Other Assets, NoncurrentUSD | 587,000Source | — | 1,344,000Source | 1,697,000Source | — | 1,344,000Source | 1,698,000Source | — | 596,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 123,144,000Source | 22,711,688Source | 145,752,000Source | 102,152,000Source | 14,846,193Source | 146,350,000Source | 98,681,000Source | 11,730,750Source | 119,952,000Source | 24,542,143Source | 13,049,096Source | 8,076,603Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 689,108,000Source | 675,343,443Source | 1,021,980,000Source | 683,962,000Source | 671,998,583Source | 786,313,000Source | 680,664,000Source | 670,185,376Source | 766,781,000Source | 677,414,830Source | 609,969,236Source | 129,192,291Source |
| Retained Earnings (Accumulated Deficit)USD | -400,486,000Source | -189,988,477Source | -594,423,000Source | -330,757,000Source | -154,598,140Source | -532,618,000Source | -275,537,000Source | -130,331,128Source | -462,911,000Source | -235,592,989Source | -116,657,472Source | -80,650,212Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 278,000Source | 2,833,970Source | 630,000Source | 520,000Source | 3,256,907Source | 322,000Source | 2,387,000Source | 2,693,096Source | 604,000Source | 4,996,769Source | 2,357,621Source | 350,946Source |
| Stockholders' Equity Attributable to ParentUSD | 288,906,000Source | 488,195,325Source | 428,195,000Source | 353,731,000Source | 520,663,737Source | 254,024,000Source | 407,520,000Source | 542,553,731Source | 304,481,000Source | 446,825,002Source | 495,675,683Source | 48,898,296Source |
| Liabilities and EquityUSD | 414,335,000Source | 518,213,328Source | 573,947,000Source | 460,096,000Source | 544,877,690Source | 400,374,000Source | 511,262,000Source | 564,117,138Source | 424,433,000Source | 477,933,282Source | 526,540,115Source | 76,843,301Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 48,368,000Source | 20,081,020Source | 45,392,000Source | 27,361,000Source | 12,281,964Source | 46,114,000Source | 23,981,000Source | 8,910,520Source | 45,478,000Source | 22,463,861Source | 9,965,680Source | 7,665,446Source |
| Operating Lease, Liability, CurrentUSD | 1,499,000Source | 1,444,893Source | 1,246,000Source | 1,550,000Source | 1,321,727Source | 920,000Source | 1,432,000Source | 1,304,426Source | 1,234,000Source | 1,371,962Source | 1,197,876Source | 153,629Source |
| Operating Lease, Liability, NoncurrentUSD | 486,000Source | 1,935,709Source | 772,000Source | 836,000Source | 2,022,280Source | 865,000Source | 1,142,000Source | 2,357,495Source | 374,000Source | 1,457,598Source | 2,499,990Source | 128,951Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 2,285,000Source | 7,306,315Source | — | 4,213,000Source | 9,367,760Source | — | 5,061,000Source | 9,832,657Source | 0Source | 6,566,137Source | 17,815,336Source | 19,868,402Source |
| Additional Financial Items | ||||||||||||
| Long-term DebtUSD | 73,741,000Source | — | 99,514,000Source | 73,381,000Source | — | 99,018,000Source | 73,022,000Source | — | 74,100,000Source | — | — | — |
| Cash, Cash Equivalents, and Short-term Investments | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -70,694,000Source | -36,114,000Source | -61,805,000Source | -56,051,000Source | -69,707,000Source | -40,559,000Source | -230,321,000Source | -121,244,400Source | -44,079,117Source | -64,506,051Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 845,000Source | 378,000Source | 2,616,000Source | 1,384,729Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 13,355,000Source | 2,290,000Source | 12,898,000Source | 7,281,596Source | 7,106,005Source | 9,654,778Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -6,173,000Source | 3,013,000Source | 20,560,000Source | 7,154,795Source | 1,582,712Source | -1,314,318Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -66,286,000Source | -38,140,000Source | -196,007,000Source | -116,587,263Source | -42,778,167Source | -55,893,900Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 98,000Source | 56,246,000Source | 202,992,000Source | -205,595,299Source | -25,184,324Source | -32,340,593Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 35,000Source | 35,000Source | 519,520Source | 284,634Source | 16,009Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | 50Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 30,644,000Source | 73,122,000Source | 145,997,000Source | 51,311,708Source | 479,701,508Source | 119,692,735Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -36,027,000Source | 91,140,000Source | 154,091,000Source | -270,742,888Source | 411,663,710Source | 31,466,782Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 350,736,000Source | 375,655,000Source | 477,905,000Source | 306,681,000Source | 298,490,000Source | 271,566,000Source | 334,517,000Source | 180,426,449Source | 451,169,337Source | 39,505,627Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,819,000Source | 0Source | 5,059,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 799,000Source | 147,294Source | 41,713Source | 4,312Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,708,000Source | 1,843,000Source | 2,546,000Source | 3,309,000Source | 13,355,000Source | 2,290,000Source | 12,898,000Source | 7,281,596Source | 7,106,005Source | 9,654,778Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | 13,158Source | 12,358Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | -267,000Source | -27,000Source | — | 378,000Source | 56,000Source | -35,000Source | 599,000Source | -42,186Source | 151,493Source | 325,317Source |
| General and Administrative ExpenseUSD | — | — | 10,799,000Source | 7,376,000Source | 11,439,000Source | 10,936,000Source | 15,509,000Source | 11,026,000Source | 41,972,000Source | 30,319,780Source | 22,321,216Source | 23,012,463Source |
| Income Tax Expense (Benefit)USD | — | — | 115,000Source | 92,000Source | 90,000Source | 95,000Source | 622,000Source | 153,000Source | 611,000Source | 282,199Source | 94,388Source | 36,366Source |
| InterestExpenseNonoperatingUSD | — | — | 3,198,000Source | 0Source | 2,632,000Source | 2,037,000Source | 2,269,000Source | 18,000Source | 7,248,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -69,729,000Source | -35,390,000Source | -61,805,000Source | -55,220,000Source | -69,707,000Source | -39,944,000Source | -227,318,000Source | -118,935,517Source | -36,007,260Source | -49,973,249Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -965,000Source | -724,000Source | 0Source | -831,000Source | 0Source | -615,000Source | -3,003,000Source | -2,308,883Source | -8,071,857Source | -14,532,802Source |
| Operating ExpensesUSD | — | — | 71,434,000Source | 43,112,000Source | 61,660,000Source | 60,698,000Source | 70,024,000Source | 47,485,000Source | 244,834,000Source | 143,091,082Source | 54,123,096Source | 65,061,417Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 399,882Source | 155,552Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 591,732Source |
| Pension Expense (Reversal of Expense), NoncashUSD | — | — | — | — | — | — | 11,000Source | -4,000Source | -58,000Source | 1,300Source | -85,254Source | 304,031Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | 24,467,000Source | 73,022,000Source | 73,022,000Source | — | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 59,166,000Source | 144,829,000Source | 468,401,000Source | 145,202,997Source | 150,833,021Source | 9,901,437Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 91,298Source | — | — | — | 100,000Source | — | 242,004Source | — | — |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -71,434,000Source | -43,112,000Source | -61,660,000Source | -60,698,000Source | -70,024,000Source | -47,485,000Source | -244,834,000Source | -143,091,082Source | -54,123,096Source | -65,061,417Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 591,732Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -229,710,000Source | -120,962,201Source | -43,984,729Source | -64,469,685Source |
| Income Tax Expense (Benefit)USD | — | — | 115,000Source | 92,000Source | 90,000Source | 95,000Source | 622,000Source | 153,000Source | 611,000Source | 282,199Source | 94,388Source | 36,366Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -965,000Source | -724,000Source | 0Source | -831,000Source | 0Source | -615,000Source | -3,003,000Source | -2,308,883Source | -8,071,857Source | -14,532,802Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -69,729,000Source | -35,390,000Source | -61,805,000Source | -55,220,000Source | -69,707,000Source | -39,944,000Source | -227,318,000Source | -118,935,517Source | -36,007,260Source | -49,973,249Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.1Source | -0.56Source | -0.84Source | -0.87Source | -0.98Source | -0.63Source | -3.53Source | -1.89Source | -0.73Source | -1.7Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.1Source | -0.56Source | -0.84Source | -0.87Source | -0.98Source | -0.63Source | -3.53Source | -1.89Source | -0.73Source | -1.7Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 63,369,984Source | 62,896,782Source | 73,915,296Source | 63,282,728Source | 71,273,650Source | 63,233,788Source | 64,463,889Source | 62,870,237Source | 49,122,534Source | 29,361,353Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 63,369,984Source | 62,896,782Source | 73,915,296Source | 63,282,728Source | 71,273,650Source | 63,233,788Source | 64,463,889Source | 62,870,237Source | 49,122,534Source | 29,361,353Source |
| Interest Expense (non-operating)USD | — | — | 3,198,000Source | 0Source | 2,632,000Source | 2,037,000Source | 2,269,000Source | 18,000Source | 7,248,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | -267,000Source | -27,000Source | — | 378,000Source | 56,000Source | -35,000Source | 599,000Source | -42,186Source | 151,493Source | 325,317Source |
| General and Administrative ExpenseUSD | — | — | 10,799,000Source | 7,376,000Source | 11,439,000Source | 10,936,000Source | 15,509,000Source | 11,026,000Source | 41,972,000Source | 30,319,780Source | 22,321,216Source | 23,012,463Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -229,118,000Source | -120,417,158Source | -43,469,946Source | -62,115,251Source |
| Operating ExpensesUSD | — | — | 71,434,000Source | 43,112,000Source | 61,660,000Source | 60,698,000Source | 70,024,000Source | 47,485,000Source | 244,834,000Source | 143,091,082Source | 54,123,096Source | 65,061,417Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 399,882Source | 155,552Source |
| Research and Development ExpenseUSD | — | — | 60,635,000Source | 35,736,000Source | 50,221,000Source | 49,762,000Source | 54,515,000Source | 36,459,000Source | 202,862,000Source | 112,771,302Source | 31,801,880Source | 42,048,954Source |
Offerings
Registration 333-298192
Filing attachments
ea030102401ex4-1.htm · S-3ASR · 2026-08-10
Exhibit 4.1 MOONLAKE IMMUNOTHERAPEUTICS, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── …
Read attachment ↗ea030102401ex4-2.htm · S-3ASR · 2026-08-10
Exhibit 4.2 MOONLAKE IMMUNOTHERAPEUTICS, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Section 1.01 …
Read attachment ↗ea030119101ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ea030119101ex99-1.htm PRESS RELEASE, DATED AUGUST 10, 2026 Exhibit 99.1 MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% …
Read attachment ↗ea029576601ex4-1.htm · 8-K · 2026-06-25
EX-4.1 3 ea029576601ex4-1.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 MOONLAKE IMMUNOTHERAPEUTICS PRE-FUNDED WARRANT TO PURCHASE CLASS A ORDINARY SHARES Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: June 25, 2026 ─────────────────────────────────────────────────────────── MoonLake Immunotherapeutics, a Cayman Islands exempted company (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of whi…
Read attachment ↗ea029539901ex99-1.htm · 8-K · 2026-06-22
EX-99.1 2 ea029539901ex99-1.htm PRESS RELEASE, DATED JUNE 21, 2026 Exhibit 99.1 MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than th…
Read attachment ↗ea029539901ex99-2.htm · 8-K · 2026-06-22
EX-99.2 3 ea029539901ex99-2.htm SLIDE PRESENTATION, DATED JUNE 22, 2026 Exhibit 99.2 © 2026 | Proprietary | MoonLake TX MoonLake Immunotherapeutics Investor Day June 22nd, 2026 © 2026 | Proprietary | MoonLake TX Source: Welcome to our Investor Day MoonLake Corporate Strategy Agenda Sub-topics Topic Speaker Timing Proposed Label Update on BLA progress BLA strategy Jorge 20 mins Welcome MLTX & SLK summary Introduction Jorge 10 mins Final Week 52 Phase 3 VELA data Update on VELA-TEEN data Fin…
Read attachment ↗